Good morning, everyone, and welcome to the middle of the week. You made it this far, so why not continue? Consider the alternatives, after all. Meanwhile, we would like to note the passing of the Morning Mayor, who taught us a valuable lesson: Every new day should be unwrapped like a precious gift. While you tug on the ribbon, you can also peruse some of the items we have assembled below. Hope your day goes well and please do keep in touch. We appreciate your tips, criticism and suggestions.
Novartis (NVS) is not seeing any disruption to its supply chain due to the coronavirus outbreak, Reuters reports. The company has asked its staff in China to work from home until Feb. 10 while suspending business travel to and from Wuhan, the city where the coronavirus is believed to have emerged from a food market. Novartis chief executive Vas Narasimhan says the situation was developing very quickly and must be monitored, but for now he believes its business will emerge unscathed.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
What is it?
STAT Plus is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What’s included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
